Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19399109 | 0.84 | TAAR1 (0.44) | TAAR1AOC3SLC6A2SLC6A4ACP3 | |
| SCHEMBL19742792 | 0.81 | TAAR1 (0.49) | TAAR1HTR2AHRH1AOC3SLC6A2 | |
| SCHEMBL10324223 | 0.81 | SLC6A2 (0.49) | TAAR1HTR2AHRH1AOC3SLC6A2 | |
| SCHEMBL8722245 | 0.81 | TAAR1 (0.49) | TAAR1HTR2AHRH1SLC6A2SLC6A4 | |
| SCHEMBL13850017 | 0.80 | TAS1R3 (0.45) | TAAR1AOC3SLC6A2SLC6A4ACP3 | |
| SCHEMBL6055393 | 0.80 | TAS1R3 (0.45) | TAAR1AOC3SLC6A2SLC6A4ACP3 | |
| SCHEMBL3196398 | 0.80 | ACP3 (0.42) | TAAR1AOC3SLC6A2SLC6A4ACP3 | |
| SCHEMBL14402512 | 0.80 | TAS1R3 (0.45) | TAAR1AOC3SLC6A2SLC6A4ACP3 | |
| SCHEMBL13849155 | 0.80 | TAS1R3 (0.45) | TAAR1AOC3SLC6A2SLC6A4ACP3 | |
| SCHEMBL8791290 | 0.80 | TAAR1 (0.43) | TAAR1HTR2AHRH1AOC3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777706-B | A kind of 3- [(benzo [d] [1,3] dioxolanes -4- base)-oxygroup] -3- arylprop aminated compounds and its application | 江苏恩华药业股份有限公司 | 2019-08-23 | — | — | CN | disclosed |
| US-10093644-B2 | 3-[(Benzo[D][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine type compounds and applications thereof | NHWA PHARMA. CORPORATION (CN) | 2018-10-09 | — | — | US | disclosed |
| US-20170369466-A1 | 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYLPROPYLAMINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | NHWA PHARMA. CORPORATION (CN) | 2017-12-28 | — | — | US | disclosed |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093644-B2 | 3-[(Benzo[D][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine type compounds and applications thereof | TPH1, MAOA, MAOB | TAAR1 98/4885HTR2A 34/4885HRH1 1226/4885 |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TAAR1 2019/4885HTR2A 1685/4885HRH1 149/4885 |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TAAR1 2019/4885HTR2A 1685/4885HRH1 149/4885 |
| US-20170369466-A1 | 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYLPROPYLAMINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | TPH1, MAOA, MAOB | TAAR1 98/4885HTR2A 34/4885HRH1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.